Ageliki Karatza | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Prof. Dr. Ageliki Karatza | Clinical Trials | Best Researcher Award

University of Patras Medical School | Greece

Prof. Dr. Ageliki Karatza is a distinguished figure in the field of Paediatrics and Paediatric Cardiology, recognized for her exceptional academic achievements, clinical expertise, and research contributions spanning decades. Her journey began with her admission to the University of Patras Medical School through highly competitive national examinations, where she graduated with one of the top degrees in her class. Following her graduation, she completed her rural medical service before pursuing specialization in General Paediatrics, earning her board certification after extensive training and rigorous examinations.Her dedication to advancing paediatric care led her to prominent institutions in London, including Imperial College, Hammersmith and Queen Charlotte’s Hospitals, and the Royal Brompton Hospital, where she gained substantial clinical and research experience in Paediatric and Perinatal Cardiology. Her fellowship and registrar positions in Neonatal and Paediatric Cardiology enabled her to develop expertise in managing complex cardiovascular conditions in neonates, infants, and children. Upon returning to Greece, she held key positions in academic medicine at the University of Patras Medical School, progressing through roles as Clinical Lecturer, Senior Lecturer, Associate Professor, and ultimately achieving the rank of Professor in Paediatrics-Paediatric Cardiology.In addition to her teaching responsibilities, she has been instrumental in organizing and delivering undergraduate and postgraduate education, serving as a tutor in multiple master’s programs and teaching medical students and trainees at various levels. Her role as the ERASMUS representative in Paediatrics has facilitated international academic collaborations and student exchanges, strengthening the global reach of the University of Patras Medical School. Clinically, she has been responsible for the Paediatric Cardiology outpatient clinic, providing daily consultations and urgent care services for the entire Southwestern Greece region, ensuring that paediatric patients receive timely and specialized cardiac care.

Profile: Google Scholar

Featured Publications

Karatza, A. A., Wolfenden, J. L., Taylor, M. J. O., Wee, L., Fisk, N. M., & Gardiner, H. M. (2002). Influence of twin-twin transfusion syndrome on fetal cardiovascular structure and function: Prospective case–control study of 136 monochorionic twin pregnancies. Heart, 88(3), 271–277.

Karatza, A. A., Bush, A., & Magee, A. G. (2005). Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. International Journal of Cardiology, 100(2), 267–273.

Davlouros, P. A., Karatza, A. A., Gatzoulis, M. A., & Shore, D. F. (2004). Timing and type of surgery for severe pulmonary regurgitation after repair of tetralogy of Fallot. International Journal of Cardiology, 97, 91–101.

Gardiner, H. M., Taylor, M. J. O., Karatza, A., Vanderheyden, T., Huber, A., … (2003). Twin-twin transfusion syndrome: The influence of intrauterine laser photocoagulation on arterial distensibility in childhood. Circulation, 107(14), 1906–1911.

Fouzas, S., Karatza, A. A., Davlouros, P. A., Chrysis, D., Alexopoulos, D., … (2014). Neonatal cardiac dysfunction in intrauterine growth restriction. Pediatric Research, 75(5), 651–657.

Karatza, A. A., Giannakopoulos, I., Dassios, T. G., Belavgenis, G., Mantagos, S. P., … (2011). Periconceptional tobacco smoking and isolated congenital heart defects in the neonatal period. International Journal of Cardiology, 148(3), 295–299.

Tsintoni, A., Dimitriou, G., & Karatza, A. A. (2020). Nutrition of neonates with congenital heart disease: Existing evidence, conflicts, and concerns. The Journal of Maternal-Fetal & Neonatal Medicine, 33(14), 2487–2492.

Anthracopoulos, M., Karatza, A., Liolios, E., Triga, M., Triantou, K., & Priftis, K. (2001). Prevalence of asthma among schoolchildren in Patras, Greece: Three surveys over 20 years. Thorax, 56(7), 569–571.

Albert Eisenbarth | Clinical Trials | Best Scholar Award

Published on by Top Pharmaceutical

Dr. Albert Eisenbarth | Clinical Trials | Best Scholar Award

Entomologe at Bundeswehr Hospital Hamburg | Germany

Dr. Albert Eisenbarth is a biologist specializing in parasitology, vector biology, and emerging infectious diseases. He earned his doctorate at the University of Tübingen, focusing on Onchocerca ochengi and its relevance to river blindness epidemiology. His career spans international research assignments across Africa, Asia, and Europe, contributing to studies on vector-borne diseases, zoonotic pathogens, and host-parasite interactions. Dr. Eisenbarth has worked at prestigious institutions including the Friedrich Loeffler Institute for Animal Health and the University of Tübingen. With over a decade of field and laboratory expertise, his work bridges veterinary medicine, parasitology, and global health, advancing infectious disease control strategies.

Publication Profile 

Scopus

Education 

Dr. Albert Eisenbarth completed his MSc in Parasitology at the Institute of Tropical Medicine, University of Tübingen, where he conducted his thesis on anisakid nematodes in Australian waters. He pursued doctoral studies at the University of Tübingen, earning his Doctor of Biology degree with a thesis on the biology of Onchocerca ochengi and its epidemiological implications for river blindness. His academic training also included international research exchanges at the University of Melbourne, the Royal Melbourne Institute of Technology, the University of Cape Town, and Kasetsart University in Bangkok. His education combines parasitology, vector biology, and tropical infectious disease research.

Experience 

Dr. Albert Eisenbarth has held diverse research and professional roles. He served as a Research Fellow at the Friedrich Loeffler Institute for Animal Health, working on novel and emerging infectious diseases. Previously, he completed his doctoral and postdoctoral research at the University of Tübingen and in Cameroon within the Onchocerciasis Programme. His career includes positions as Clinical Data Manager at Kendle GmbH and scientific assistant roles at the University of Tübingen. He has undertaken extensive international assignments in Mozambique, Mauritania, Cameroon, Thailand, France, Australia, and South Africa. His expertise encompasses parasitology, vector ecology, epidemiology, and zoonotic disease transmission at the human-animal interface.

Awards and Honors 

Dr. Albert Eisenbarth has received multiple awards and grants for his scientific contributions. He co-coordinated major DFG-funded projects investigating zoonotic viral transmission, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever in Africa. As principal investigator, he secured a RiSC Young Scientist grant for research on genetic susceptibility to tick-borne diseases in African cattle. His international collaborations earned him a South East Asia–European Union NET II Fellowship, supporting One Health research. He has also been recognized with travel grants from the German Society for Parasitology and the Erwin Riesch Foundation. Additionally, he was awarded DAAD fellowships for both MSc and doctoral studies.

Research Focus 

Dr. Albert Eisenbarth research focuses on parasitology, vector-borne diseases, and zoonotic infections affecting both human and animal health. He has conducted extensive work on the epidemiology of Onchocerca volvulus and Onchocerca ochengi, contributing to onchocerciasis control strategies. His studies include the diversity, abundance, and pathogen carriage of hematophagous vectors such as mosquitoes and ticks in Africa. Additionally, he investigates emerging viral diseases, including Rift Valley Fever and Crimean-Congo Hemorrhagic Fever, across the livestock-wildlife-human interface. Through molecular and field-based approaches, his work integrates parasitology, virology, and epidemiology, providing valuable insights for global health, One Health initiatives, and disease elimination programs.

Publication Top Notes

Molecular detection of Leishmania (Sauroleishmania) adleri (Trypanosomatida: Trypanosomatidae) in Sergentomyia sp. sand flies (Diptera: Psychodidae) in Mali and Niger

Mosquito survey in Mauritania: Detection of Rift Valley fever virus and dengue virus and the determination of feeding patterns

Conclusion

Dr. Albert Eisenbarth possesses the academic excellence, research productivity, and global health relevance that make him a strong candidate for the Research for Best Scholar Award. His innovative studies on parasitic and vector-borne diseases, coupled with his ability to secure competitive grants and engage in international collaborations, demonstrate outstanding scholarly merit. With continued expansion into broader leadership and translational activities, he is well-positioned to further influence the fields of parasitology, epidemiology, and infectious disease research. His track record aligns with the award’s goal of recognizing impactful and forward-looking scientific scholarship.

Premal Thaker | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Premal Thaker | Clinical Trials | Best Researcher Award

Dr. Premal Thaker at Washington University School of Medicine, United States.

Dr. Premal Thaker is a renowned gynecologic oncologist and professor at Washington University, St. Louis. With a medical degree from Allegheny University and advanced training at MD Anderson Cancer Center, she has led impactful clinical research in ovarian and endometrial cancers 🧪. As Director of Gynecologic Oncology Clinical Research and Division Chief (2025–present), her leadership is pivotal in advancing cancer therapies. A respected speaker, grant recipient, and editorial board member 📚, Dr. Thaker has earned numerous accolades including “Best Doctors in America” and “Castle Connolly Top Doctor” 🏅. Her dedication to women’s health continues to inspire globally.

Publication Profile 

Scopus

Education

Dr. Premal Thaker’s illustrious academic journey began with a BA in Biology from Villanova University 🎓, followed by an MD from Allegheny University and an MS in Cancer Biology from the University of Texas 🧬. She completed specialized training in gynecologic oncology at MD Anderson Cancer Center and recently attended a leadership course at Harvard 🏛️. Dr. Thaker has held esteemed positions at Washington University, advancing from Assistant Professor to Division Chief of Gynecologic Oncology 👩‍⚕️. A distinguished researcher and educator, she is also the David and Lynn Mutch Distinguished Professor and Director of Clinical Research.

Awards

Dr. Premal Thaker has received numerous accolades throughout her distinguished career in gynecologic oncology 🎖️. Beginning with academic honors such as the Dean’s List and Alpha Epsilon Delta Honor Society in the early 1990s 📚, she went on to earn prestigious awards for scientific presentations and publications, including the J.G. Moore Award 🧪 and GCF/Eli Lilly Fellow Award 🧬. Recognized as one of the Best Doctors in St. Louis (2013–2025) and America (2020–2024) 👩‍⚕️, she was also named a Castle Connolly Top Doctor and Fellow of AGOS. In 2025, she joined Avant-Garde Health’s Research All-Stars.

Research Focus 

Dr. Premal Thaker’s research primarily centers on gynecologic oncology, with a strong focus on ovarian and endometrial cancers 🧫. Her work explores immune checkpoint inhibitors, personalized gene therapy, molecular profiling, and health disparities in clinical trial enrollment, particularly in Hispanic and Asian populations 🌍. She also investigates novel immunotherapy combinations, real-world treatment outcomes, and genomic biomarkers for therapy response and survival 🧪. Her multidisciplinary efforts contribute to precision medicine and the advancement of targeted therapies for women’s reproductive cancers, driving impactful, patient-centered innovations in oncology care.

Publication Top Notes

  • Improving diverse patient enrollment in clinical trials, focusing on Hispanic and Asian populations: recommendations from an interdisciplinary expert panel
  • OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer
  • Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial
  • Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study
  • Diverse case series of granulomatous peritonitis mimicking advanced ovarian cancer
  • Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study
  • Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis
  • Update on safety and feasibility of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer
  • Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma
  • Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Golgem Mehmetoglu | Clinical Trials | Best Researcher Award

Ms. Golgem Mehmetoglu, European University of Lefke, Cyprus

Ms. Gölgem Mehmetoğlu is a dedicated physiotherapist and academic specializing in Physiotherapy and Rehabilitation. 🎓 She earned her B.Sc. from Eastern Mediterranean University (2011–2015), her M.Sc. from European University of Lefke (2015–2017), and is currently pursuing her Ph.D. at EMU. 🧠 Her research focuses on muscle function, postural stability, and rehabilitation outcomes, with multiple publications in international journals and conference proceedings. 📝 She also teaches core courses such as Kinesiology, Biomechanics, and Manual Therapy Techniques. 👩‍🏫 Her scientific contributions and educational roles make her a valuable candidate for the Best Researcher Award.

Publication Profile

Orcid

Education

Ms. Gölgem Mehmetoğlu is a passionate professional in the field of Physiotherapy and Rehabilitation 🧘‍♀️. She completed her undergraduate studies (2011–2015) at Doğu Akdeniz University 🏛️, laying a strong foundation in clinical practice and patient care. She then pursued her Master’s degree (2015–2017) at Lefke Avrupa University 📘, deepening her knowledge in rehabilitation science. Currently, she is advancing her academic journey through a Ph.D. program at Doğu Akdeniz University (2018–present) 🧪. Her academic path reflects commitment to continuous learning and specialization in physiotherapy, contributing to healthcare with evidence-based practice and innovative research.

Academic Positions

Ms. Golgem Mehmetoğlu 🎓 is a dedicated academic in the field of physiotherapy and rehabilitation, actively engaged in teaching at the undergraduate level. She shares her expertise through a variety of core courses including Kinesiology 🤸‍♀️, Biomechanics 🦴, Normal Motor Development 🧠, and Manual Therapy Techniques (Manipulation-Mobilization I & II) 💆‍♀️. Her teaching approach combines theoretical knowledge with hands-on application, empowering students with essential clinical and analytical skills. Through her passionate involvement in education, Ms. Mehmetoğlu continues to inspire future healthcare professionals and contribute meaningfully to the advancement of physiotherapy science.

Research Focus

Ms. Gölgem Mehmetoğlu’s 🔬 research primarily focuses on musculoskeletal rehabilitation, particularly addressing chronic pain, posture correction, functional mobility, and manual therapy in physiotherapy patients. Her studies emphasize the impact of stabilization exercises 🧘‍♀️ on pain relief, posture (craniovertebral angle 📐), disability reduction, and quality of life 🌿 in conditions like chronic neck pain and lateral epicondylitis. Her work explores the integration of exercise science, biomechanics 🤸, and evidence-based physiotherapy to improve patient outcomes. Through randomized controlled trials and clinical interventions, she contributes valuable knowledge to rehabilitation sciences and therapeutic exercise interventions.

Publication Top Notes

Effect of Postural Stabilization Exercises in Combination with Cervical Stabilization Exercises on Craniovertebral Angle, Pain, Disability, and Quality of Life in Patients with Chronic Neck Pain: A Randomized Controlled Trial

The Effects of Muscle Strength and Muscle Endurance on Upper Extremity Functions of Lateral Epicondylitis Patients

The Pain in the Canon of Medicine: Types, Causes, and Treatment

Zhumin Cao | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Zhumin Cao | Clinical Trials | Best Researcher Award

Prof. Zhumin Cao, The Seventh People’s Hospital of Chongqing, China

Prof. Zhumin Cao is a dedicated clinician and researcher in vascular diseases 🫀, with extensive experience in both basic and clinical research. He has served as a Visiting Scholar at Ajoy University Hospital 🇰🇷 and Carl Gustav Carus University Hospital 🇩🇪. Prof. Cao has led five funded research projects and published 20+ papers, including 10+ SCI articles with a cumulative impact factor of 40+ 📊. His current focus is on early intracavitary treatment of pulmonary embolism, pioneering innovations in patient care. He is also a reviewer for Angiology and Frontiers 📝.

Publication Profile

Scopus

Education

Prof. Zhumin Cao has dedicated his career to clinical and basic research in vascular diseases 🫀. He has served as a Visiting Scholar at Ajoy University Hospital in South Korea 🇰🇷 and University Hospital Carl Gustav Carus in Germany 🇩🇪. His leadership includes two provincial and three departmental-level projects 📊. He actively contributes to the scientific community as a peer reviewer for Angiology and Frontiers 📝. Prof. Cao has authored over 20 research papers, including 10+ SCI-indexed publications, with a combined impact factor of 40+, and a single article IF reaching 11.4 🌟.

Areas of Research

Prof. Zhumin Cao specializes in the field of vascular diseases 🫀, with a primary research focus on the early treatment of pulmonary embolism 🫁—a life-threatening and time-sensitive condition that poses significant challenges in clinical practice ⏱️. His work aims to improve therapeutic strategies and patient outcomes through intracavitary interventions and innovative approaches in vascular care 💉. By bridging clinical application and basic research, Prof. Cao’s studies contribute meaningfully to the development of evidence-based practices in cardiovascular medicine 🌍. His dedication supports advancements in critical care and interventional procedures that save lives every day ❤️.

Research Focus

Prof. Zhumin Cao’s research delves into the role of Interleukin-6 (IL-6) in reshaping the tumor microenvironment 🧫, a key factor in cancer progression and resistance to therapy. His work explores how IL-6-driven changes affect immune cell behavior and tumor dynamics 🧬. By understanding this cytokine’s influence, he aims to enhance the effectiveness of cancer immunotherapy 💉, offering new avenues for targeted treatments. This research bridges oncology and immunology, contributing to breakthroughs in precision medicine 🧠. Prof. Cao’s findings could lead to improved outcomes for patients battling aggressive cancers through innovative immunomodulatory strategies 🎯.

Publication Top Notes

Interleukin-6 (IL-6)-associated tumor microenvironment remodelling and cancer immunotherapy

Serefnur Ozturk | Clinical Trials | Women Researcher Award

Published on by Top Pharmaceutical

Serefnur Ozturk | Clinical Trials | Women Researcher Award

Prof Serefnur Ozturk, Selcuk University Faculty of Medicine, Turkey

Prof. Şerefnur Öztürk is a leading expert in Neurology and Neurointensive Care, currently serving as the Head of the Neurology Department at Selcuk University, Turkey. She has held prominent roles including Vice Dean of the Faculty of Medicine (1996-2020) and President of the Turkish Neurological Society (2014-2021). With significant international influence, she contributes to the European Academy of Neurology and World Stroke Organization. She has led pivotal projects and trials in stroke and COVID-19-related neurological care. Prof. Öztürk is an acclaimed researcher with numerous influential publications in neurology.

Publication Profile

scopus

Education

Prof. Serefnur Ozturk has an impressive educational background. She began her medical studies at Ankara University Medical Faculty, where she earned her degree between 1980 and 1987. Her academic journey continued with a prestigious NATO Fellowship at Arizona University’s Stroke Center in 1993, further enhancing her expertise. In 1998, she advanced her knowledge in neurology and intensive care at Pittsburgh University, where she studied in their renowned Neurology and Intensive Care Department. These experiences have shaped Prof. Ozturk into a leading figure in her field. 🏥🎓🧠

Internship and Residencies

Prof. Serefnur Ozturk completed her internship at Ankara University Medical Faculty, where she gained valuable hands-on experience. Following this, she pursued her residency at Ankara Numune Research and Education Hospital, further honing her medical skills. Prof. Ozturk’s dedication to her field is reflected in her board certification, earning the Turkish Neurological Board Council Certificate. This certification recognizes her extensive expertise in neurology, solidifying her status as a trusted professional in her area of specialization. Her journey through internships, residencies, and board certification showcases her commitment to excellence. 🏥💉🧑‍⚕️🧠

Experiences

Prof. Serefnur Ozturk holds numerous prestigious leadership roles in neurology. She served as the President of the Turkish Neurological Society from 2014 to 2021 and is currently a member of various important committees, including the European Academy of Neurology (EAN) COVID-19 Task Force and the World Stroke Organization Global Policy Committee. Additionally, she is the Vice President of the European Environmental Neurology Society and has held positions within the World Federation of Neurology (WFN), including President of the Migrant Neurology Specialty Group. Prof. Ozturk is dedicated to advancing stroke care, cerebrovascular diseases prevention, and diversity in neurology. 🧠🌍👩‍⚕️🏥

Projects

Prof. Serefnur Ozturk has played a pivotal role in several major clinical trials and registries. She is the Principal Investigator of the EAN ENERGY COVID-19 Registry and the ENSEMBLE study, showcasing her leadership in critical research. Additionally, Prof. Ozturk serves as the National Coordinator for the Turkish COVID-19 Registry, the ENOS Trial, and TICH-2. Her expertise extends to key studies like the PERFORM Study (Phase III), FACT (Phase IV), and NAVIGATE-ESUS, where she also holds significant leadership positions. Her contributions to clinical research have greatly impacted neurology and stroke care. 🔬🧠🌍💉

Research Focus

Prof. Şerefnur Öztürk’s research focus lies predominantly in neurology, with a special emphasis on the neurological impacts of COVID-19, ischemic stroke, and innovative prognostic tools like the Selcuk Score. Her work is pivotal in advancing the understanding of how pandemics influence neurological care and the management of post-pandemic risks. Additionally, Prof. Öztürk contributes to cutting-edge stroke prevention and rehabilitation technologies, including web-based solutions. Her contributions drive progress in neuro-COVID research, stroke management, and global neurological health policies, showcasing her commitment to improving outcomes for patients worldwide. 🌍🧠💻

Publication Top Notes

The European Academy of Neurology NeuroCOVID-19 Task Force: A lesson for the future

Muscle mass as a modifier of stress response in acute ischemic stroke patients

Management of patients with neurological diseases considering post-pandemic coronavirus disease 2019 (COVID-19) related risks and dangers — An updated European Academy of Neurology consensus statement

The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data from 121 Surgically Treated Participants from the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial

General neurology: Current challenges and future implications

Climate Change and Stroke: A Topical Narrative Review

Dvora Joseph Davey | Clinical Trials | Best Researcher Award

Published on by Top Pharmaceutical

Dvora Joseph Davey | Clinical Trials | Best Researcher Award 

Dr Dvora Joseph Davey, University of California, Los Angeles, UCLA, South Africa

Dr. Dvora Joseph Davey is a distinguished epidemiologist with a focus on infectious diseases, particularly HIV and STIs. Holding a Ph.D. in Epidemiology from UCLA, her research, mainly in sub-Saharan Africa, aims to reduce the burden of HIV through innovative interventions. As a Principal Investigator in clinical trials, Dr. Davey has contributed significantly to global HIV prevention efforts, especially for pregnant women. She is actively involved in policy-making with groups like the WHO and NIH, shaping global health initiatives. Her leadership, extensive research, and mentorship in global health make her an exemplary figure in public health. 🌍🔬💉

Publication Profile

google scholar

scopus

orcid

Education

Dr. Dvora Joseph Davey has an impressive academic background, beginning with a B.A. in International Affairs and French from the University of Colorado, Boulder, in 1998. She went on to earn a Master of Public Health (M.P.H.) in Population and Reproductive Health Sciences from Columbia University in 2003. Dr. Davey completed her Ph.D. in Epidemiology at the University of California, Los Angeles, in 2016, followed by a fellowship in Epidemiology of HIV at the University of North Carolina in 2017. She furthered her expertise with a postdoctoral fellowship in Global HIV Prevention at UCLA in 2018. 🌍📚

Scientific Appointments

Dr. Dvora Joseph Davey has held several prestigious positions throughout her career. Currently, she serves as an Associate Professor in Infectious Diseases and Epidemiology at UCLA’s School of Medicine and School of Public Health, respectively. She also holds honorary roles at the University of Cape Town and Desmond Tutu Health Foundation. Dr. Davey’s research includes being the Principal Investigator on a study about sexual behavior and PrEP acceptability. Her past positions include HIV Director at Population Services International in Mozambique and Director at the Rwanda-Emory HIV Research Group. With her diverse roles, Dr. Davey has had a significant global impact. 🌍🩺📊

Professional Memberships

Dr. Dvora Joseph Davey has made significant contributions to the field of HIV and reproductive health, serving as an Assistant Editor for renowned journals such as AIDS, JIAS, and PloS Global Health. She is also an active member of the South African Clinical Research Association and the American Public Health Association. Her honors include invitations to present at major conferences like HIVR4P 2024 in Peru and WHO Working Group meetings. Dr. Davey has co-chaired several influential research working groups, including on PrEP in pregnancy, and received multiple awards, including UCLA’s Epidemiology Department Summer Fellowship. 🌍📚🎤

Awards

Dr. Dvora Joseph Davey is a renowned researcher whose work focuses on HIV prevention and treatment, particularly in pregnant and breastfeeding women. Her studies address key challenges in high HIV incidence communities, especially in Sub-Saharan Africa. Dr. Davey investigates Pre-exposure Prophylaxis (PrEP) access, adherence, and effectiveness among pregnant women, emphasizing the need for female-controlled HIV prevention methods during vulnerable periods. Additionally, she explores the integration of STI testing, alcohol use, and the impact of intimate partner violence on HIV risk. Her contributions significantly influence HIV-related healthcare policies, aiming to reduce transmission and improve outcomes in these populations. 👩‍🔬🌍💉

Policy Involvement

Dr. Dvora Joseph Davey has made significant contributions to national and international HIV and STI policy-making. Her leadership in key working groups, including the National PrEP and Prevention of Vertical Transmission of HIV Working Groups, as well as the World Health Organization’s Working Group on Long-Acting PrEP in pregnancy, highlights her expertise and influence. These positions enable Dr. Davey to play a pivotal role in translating scientific research into actionable policies, ensuring her work impacts not only the scientific community but also global health policies. Her efforts amplify the reach of her research, making a lasting impact on public health worldwide. 🌍🩺💉

Leadership

Dr. Dvora Joseph Davey’s leadership in managing large-scale clinical trials and mentoring emerging public health and epidemiology professionals showcases her dedication to education and capacity-building in global public health. As a recipient of the prestigious NIH/Fogarty International Research Scientist Development Award (IRSDA) and the follow-on R01 award, Dr. Davey has solidified her position as a thought leader in the field. Her commitment to fostering continuous learning and improvement within the global health community reflects her deep influence and dedication to advancing public health practices worldwide. 🎓🌍💉👩‍🔬

Ongoing Projects

Dr. Dvora Joseph Davey’s ongoing research, supported by NIH and Gilead Corporation, plays a crucial role in addressing HIV within vulnerable populations. Her work on projects like PrEP-PP and SCOPE-PP, alongside innovative initiatives such as a community-based peer-led intervention to tackle alcohol use and HIV risk in pregnant women, highlights her proactive approach to solving complex public health challenges. Dr. Davey’s research aims to create effective, targeted solutions that address the unique needs of at-risk communities, contributing significantly to advancing HIV prevention and care efforts. 💡🧑‍🔬🩺🌍

Research Focus

Dr. Dvora Joseph Davey is a prominent researcher specializing in HIV prevention, sexually transmitted infections (STIs), and maternal health. Her work focuses on pre-exposure prophylaxis (PrEP) for HIV, examining its safety and efficacy among pregnant and postpartum women. She also explores STI diagnostics, point-of-care testing, and the prevalence of curable STIs in low- and middle-income countries. Her research seeks to improve access to health interventions, particularly for vulnerable populations like men who have sex with men and transgender women. Dr. Davey’s contributions help shape public health strategies for HIV prevention and sexual health. 🦠💉

Publication Top Notes